Table 1. Clinical Characteristics of CNS DLBCL.
| Variable | Result |
| Age at diagnosis (years) | Median: 66, range: 37–87 |
| Sex (males) | 24/59 (41%) |
| KPS | Median: 70%, range: 20–90% |
| ECOG | Mean: 2, cases ≥2: 34/58 (59%) |
| LDH* | Elevated: 16/23 (70%), range: 224-1931 units/L |
| Tumor location: | |
| Supratentorial | 52/59 (88%) |
| Infratentorial | 7/59 (12%) |
| Number of tumor masses: | |
| Single | 27/57 (47%) |
| Multiple | 30/57 (53%) |
| Deep brain structure involvement: | |
| Yes | 24/59 (41%) |
| No | 35/59 (59%) |
| Therapy: | |
| MTX | 26/43 (60%) |
| MTX, WBRT | 1/43 (2%) |
| MTX, rituximab | 1/43 (2%) |
| R-MVP | 2/43 (5%) |
| R-MVP, WBRT | 1/43 (2%) |
| R-MVP, cytarabine | 4/43 (9%) |
| R-MVP, cytarabine, WBRT | 2/43 (5%) |
| MTX, rituximab, temozolamide | 1/43 (2%) |
| MTX, rituximab, temozolamide, WBRT | 1/43 (2%) |
| MTX, rituximab, procarbazine, WBRT | 1/43 (2%) |
| MVP, cytarabine, temozolamide | 1/43 (2%) |
| MTX, thiotepa | 1/43 (2%) |
| MTX, taxol, WBRT | 1/43 (2%) |
| No therapy | 5/48 (10%) |
Abbreviations: MXT, methotrexate. WBRT, whole brain radiation therapy. R-MVP, rituximab, methotrexate, procarbazine, and vincristine.
*Normal range of LDH: 115–221 units/L.